Clinical Trials Browser

OTHER × Adenocarcinoma × Everolimus × Clear all

NCT01784861 2021-07-08

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Phase 1/2 Terminated

23 enrolled 17 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT00597506 2012-12-27

BEV/EV

Phase 2 Completed

50 enrolled 7 charts

Adenocarcinoma